CONTRACT PHARMACEUTICAL MANUFACTURING MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2026-2033)

Global contract pharmaceutical manufacturing market is estimated to be valued at USD 255.74 Bn in 2026 and is expected to reach USD 501.55 Bn by 2033, exhibiting a compound annual growth rate (CAGR) of 10.1% from 2026 to 2033.

The contract pharmaceutical manufacturing market is expected to witness significant growth over the forecast period. This growth is attributed to the increasing complexity of drug development process which is compelling pharmaceutical companies to opt for contract manufacturing. Moreover, the rising demand for generics and biologics is further the driving market growth. Additionally, growing focus of pharmaceutical companies on core competencies is resulting in the outsourcing of non-core activities like manufacturing to contract manufacturing organizations. However, high capital investment requirements for facilities and equipment as well as stringent regulatory guidelines can hamper the market growth. But focus on the modernization of manufacturing facilities coupled with emerging role of Artificial Intelligence (AI) and automation provides new avenues for contract pharmaceutical manufacturers.

  Increasing Incidence of Research and Development in Pharmaceutical Manufacturing

Demand for small molecules is considerably high compared to large molecules, owing to its various advantages in manufacturing and clinical trial studies. For instance, in November 2021, Pfizer Inc., a U.S.-based multinational pharmaceutical and biotechnology corporation, announced the successful acquisition of Trillium Therapeutics, a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer. According to the terms of the acquisition, Pfizer Inc. will purchase all shares of Trillium Therapeutics that are not already owned by Pfizer Inc. for a cash implied equity value of US$ 2.26 billion, or US$ 18.50 per share. This is 118% more expensive than Trillium Therapeutics’ 60-day weighted average price.

Insights, By Service Type: Contract Manufacturing Organization (CMO) contributes the highest share of the market owing to their end-to-end capabilities

Service type segment is sub-segmented into contract manufacturing organization (CMO) and contract research organization (CRO). The contract manufacturing organization (CMO) segment is estimated to hold 53.9% of the market share in 2026, owing to their robust end-to-end capabilities. CMOs provide extensive integrated services right from drug development and manufacturing to packaging and supply chain management. They have specialized expertise across various drug formulations like small molecules, biologics, injectables, etc. Their flexibility to scale up or down operations as per clients' changing needs is a major attraction. CMOs also offer strategic advantages to pharmaceutical companies like access to advanced manufacturing technologies and facilities without huge capital investment. This allows drug makers to focus on their core competencies of R&D and commercialization. The outsourcing of manufacturing activities to CMOs helps reduce fixed costs and ensures business continuity. Their global manufacturing footprint and experience in dealing with complex regulatory requirements of international markets provide pharmaceutical clients an easy entry into new geographies. Further, CMOs guarantee a high standard of quality and reliability through stringent compliance with CGMP norms.

Insights, By Molecule Type: Small molecules dominate the global contract pharmaceutical manufacturing market owing to their higher adoption across therapy areas

Molecule type segment is sub-segmented into small molecule and large molecule. The small molecule segment is estimated to hold 59.8% of the market share in 2026 due to the higher adoption of small molecule drugs across various therapeutic categories. A majority of existing drugs in the market are small molecule compounds which are relatively easier to develop and manufacture compared to large molecule biologics. Areas like cardiovascular, anti-inflammatory, anti-diabetic, anti-depressants, etc. extensively using small molecule-based medications. Their cost-effectiveness, well-established chemistry manufacturing and controls procedures, and simpler supply chain needs provide an advantage over large biologics. Further, the streamlined regulatory pathways and approvals for generic versions of blockbuster small molecule drugs boost their dominating presence. Compared to biologics, small molecules have a longer track record, well-known safety profiles, and mechanisms of action. This makes them a relatively lower-risk option for pharmaceutical companies. The difficulty and exorbitant costs associated with biosimilar development compared to generic versions of small molecules further consolidate their leading market share in contract manufacturing. Overall, the breadth of small molecule presence notably contributes to their ascendency in the global marketplace.

North America remains the dominant region in the global contract pharmaceutical manufacturing market and is estimated to hold 32.6% of the market share in 2026 with the U.S. being the major revenue generator. This can be attributed to the heavy presence of large pharmaceutical companies as well as contract development and manufacturing organizations in the region. Additionally, a large population opting for medicines manufactured under rigorous quality standards further aids the market growth. Despite rising manufacturing costs, North American companies prefer local manufacturing partnerships to achieve regulatory compliance and timely deliveries.

Asia Pacific has emerged as the fastest growing regional market for contract pharmaceutical manufacturing in recent years. Several factors have contributed towards this, foremost being proactive government support and initiatives to lure investments in pharmaceutical production. Countries like India and China offer low production costs, availability of skilled workforce as well as proximity to growing pharma markets of Asia Pacific and Africa. Additionally, these nations have built expertise across contract manufacturing services including active pharmaceutical ingredients production, generics development, and finished dosage formulation.

Increasing Inorganic Activities among Market Players

Increasing inorganic activities, such as agreements, partnerships, and collaborations, among market players are expected to drive the market growth over the forecast period. For instance, in September 2023, Parexel, a contract research organization (CRO), and Partex, a data-to-drugs pharma platform, inked a deal aiming to leverage artificial intelligence (AI)-powered solutions to accelerate drug discovery and development for biopharmaceutical customers worldwide and de-risk the assets in their portfolios.

• In November 2023, Daré Bioscience, Inc., a leader in women’s health innovation, and Premier Research International, LLC, a global clinical research, product development, and consulting company, announced that the companies extended their partnership agreement under which Premier Research International, LLC will continue to provide an exclusive basis contract research organization (CRO) service within the U.S. to support the clinical development of Daré Bioscience, Inc’s reproductive health portfolio
• In November, 2023, Ichor Life Sciences, a full-service contract research organization (CRO) and longevity biotechnology company, announced the launch of Ichor Clinical Trial Services. With the founding of Ichor Clinical, the company is able to serve biotechnology and pharmaceutical clients from early preclinical studies through late-stage clinical trials and U.S. Food Drug Administration approval.
• In November 2020, Catalent, Inc., a global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, announced the acquisition of Bone Therapeutics’ cell therapy manufacturing subsidiary, Skeletal Cell Therapy Support SA (SCTS), including all of its assets located in Gosselies, Belgium. This acquisition will help to expand its industry-leading cell therapy capabilities and advanced clinical and commercial supply, and create an integrated European center of excellence in cell therapy.
• In January 2020, Celltrion, a manufacturer of biosimilars from South Korea, planned to invest US$ 514 million over five years in its new plant in Wuhan, the biologics facility in China with a 120,000-liter capacity. The new facility is intended to develop and produce biologics for the local market as well as carry out contract work for the burgeoning industry of Chinese biotech firms.

*Definition: Contract pharmaceutical manufacturing is engaged in conducting various kinds of drug production and research activities for different pharmaceutical companies. In the present time, there is an extensive need for pharmaceutical contract research and manufacturing, as drug manufacturers are facing increased research and manufacturing costs resulting due to the expiration of many older drugs patents, competition from drug industry, and stringent government regulations for new drug development. Pharmaceutical manufacturers are capable to reduce manufacturing and research & development costs by outsourcing several processes that were previously done in-house, ranging from initial drug research studies to the entire manufacturing process.

Market Challenge – Labor Shortages and Skills Gaps

The global contract pharmaceutical manufacturing market is facing significant challenges due to widespread labor shortages and skills gaps. A lack of qualified workers is restricting the production capacities of contract manufacturers and hindering their ability to meet rising customer demand. Several factors are exacerbating the talent crunch. The aging workforce in developed nations is depleting the pool of experienced professionals in pharmaceutical manufacturing. Younger generations often prefer less industrial careers, weakening recruitment pipelines. Stringent immigration policies during the pandemic also reduced the flows of skilled overseas workers to countries with major contract manufacturing industries.

Market Opportunity – Increasing Launch of Novel services

Increasing adoption of organic growth strategies such as launch of novel services by the key market players is expected to drive the market growth over the forecast period. For instance, in December 2021, IQVIA, a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry, launched new research nursing and phlebotomy services to offer access to a global network of high-quality, credentialed professionals for patients participating in clinical trials. The IQVIA research nursing and phlebotomy teams possess the capability to conduct a diverse range of assessments, collect data and specimens, and provide assistance in the direct delivery and administration of investigational products to patients.

• Service Type Insights (Revenue, USD Bn, 2021 - 2033)
  • Contract Manufacturing Organization (CMO)
    • API Manufacturing
    • Final dosage form manufacturing
    • Packaging
  • Contract Research Organization (CRO)
    • Drug Discovery
    • Preclinical Studies
    • Early Phase I – IIa
    • Phase IIa – III
    • Phase IIIb – IV
    • Medical Coding and Writing
    • Monitoring
    • Clinical Data Management
    • Others (Protocol Development, etc.)
•  Molecule Type Insights (Revenue, USD Bn, 2021 - 2033)
  • Small Molecule
  • Large Molecule
• Regional Insights (Revenue, USD Bn, 2021 - 2033)
  • North America
    • U.S.
    • Canada
  • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
  • Europe
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • GCC Countries
    • Israel
    • Rest of Middle East
  • Africa
    • South Africa
    • North Africa
    • Central Africa
• Key Players Insights
  • Lonza Group
  • Boehringer Ingelheim GmbH
  • Genpact Limited
  • Accenture plc
  • Quintiles Transnational Corporation
  • Baxter 
  • Dr. Reddy’s Laboratories Ltd.
  • Aurobindo Pharma
  • Pfizer, Inc.
  • The Almac Group
  • Teva Pharmaceutical Industries Ltd.
  • Piramal Enterprises Ltd.
  • Covance, Inc.
  • Catalent, Inc.
  • Abbvie, Inc.
  • Celltrion